Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IW-3300

Other · developed by Ironwood Pharmaceuticals

Phase 2 Most advanced trial (none active)

IRWD Developer

2 Registered trials

What is IW-3300?

IW-3300 is an investigational drug studied in Healthy Volunteers, Interstitial Cystitis, Bladder Pain Syndrome.

At a glance

Drug type: Other
Therapy area: Renal & urology
Developer: Ironwood Pharmaceuticals, Inc. (IRWD)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05740007	Phase 2	Interstitial Cystitis	Terminated	IRWD
NCT05362695	Phase 1	Healthy Volunteers	Completed	IRWD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bladder Pain SyndromeHealthy VolunteersInterstitial Cystitis

More from Ironwood Pharmaceuticals

Lesinurad FDA approved IW-6118 Phase 2 IW-9179 Phase 2 MD-0727 Phase 2 MD-7246 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IRWD page.

Follow IRWD, the company behind IW-3300

See IRWD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IRWD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z